A mouse model of autosomal dominant spastic ataxia and myopathy caused by a mutation in Tuba4a

This study characterizes a novel mouse model harboring a Tuba4aQ176P mutation that recapitulates key features of human spastic ataxia type 11 and congenital myopathy type 26, providing a specific tool to investigate cell-type selective neurodegeneration and myopathy without motor neuron loss.

The Gist

Imagine your body is a massive, bustling city. Inside every cell of that city, there is a complex transportation system made of tiny, flexible railroad tracks called microtubules. These tracks are essential for moving supplies, sending messages, and keeping the cell's shape.

The tracks are built from blocks called tubulins. One specific type of block, TUBA4A, is like a specialized, high-performance rail piece used in very specific districts of the city: the brain's control center (the cerebellum) and the muscle factories.

The Discovery: A "Jerky" Mouse

Scientists at The Jackson Laboratory were running a massive experiment where they randomly tweaked the DNA of mice to see what would happen. They found one male mouse that was acting strangely. By the time he was about a month old, he started stumbling, shaking, and losing muscle mass. He looked like he was walking on a tightrope in a strong wind.

Because of his jerky walk, the scientists nicknamed the strain "Biltong" (a play on the word "jerky," since "Jerky" was already taken by another famous mouse).

The Culprit: A Single Typo

The scientists played detective to find out what went wrong. They narrowed it down to a single letter change in the mouse's genetic code—a tiny typo in the instructions for building the TUBA4A rail block.

• The Mutation: In the healthy mouse, the code says "Glutamine" (Q) at position 176. In the sick mouse, it says "Proline" (P).
• The Analogy: Imagine the railroad track is a long, smooth chain of links. The scientists found that one link was swapped for a rigid, bent piece of metal. When the tracks try to assemble, this bent piece ruins the whole structure. It's like trying to build a perfect tower of Jenga blocks, but one block is slightly warped; eventually, the whole tower wobbles and collapses.

What Happens in the Mouse?

Because of this warped block, two main things go wrong in the "Biltong" mice:

1. The Brain Glitch (Ataxia): The cerebellum is the part of the brain that coordinates smooth movement. In these mice, the "control neurons" (Purkinje cells) in the cerebellum start dying off rapidly after 30 days.
   • Result: The mouse loses its balance, shakes when it tries to move, and can't walk in a straight line. This is called ataxia.
2. The Muscle Meltdown (Myopathy): The muscles in the legs are also built using these tracks. Without the proper rails, the muscle fibers get messy, disorganized, and start to break down.
   • Result: The mouse's muscles waste away, it loses grip strength, and it can't hang onto a wire grid for long.

The Big Twist: It's Not ALS

Here is the most exciting part for medical researchers. In humans, mutations in the TUBA4A gene are known to cause a terrifying disease called ALS (Lou Gehrig's disease), where the nerves that control muscles die, leading to paralysis.

However, the "Biltong" mice do not get ALS.

• Their spinal cord motor neurons (the long wires connecting the brain to the muscles) are still alive and healthy.
• They only have problems in the brain's coordination center and the muscles themselves.

Why is this a big deal?
Think of the human disease as a fire that burns down the whole house (brain, spinal cord, and muscles). The "Biltong" mouse is like a house where only the kitchen and the living room are on fire, but the bedroom is safe.

This gives scientists a unique "controlled experiment." They can study exactly how this specific mutation damages muscles and the cerebellum without the complication of the spinal cord dying. It helps them figure out which part of the disease is caused by the mutation directly, and which parts are secondary effects.

The Human Connection

This mouse model is a mirror for human patients.

• Some humans with this mutation have Spastic Ataxia (stiff, clumsy walking).
• Others have Congenital Myopathy (weak muscles from birth).
• Some get ALS or Frontotemporal Dementia.

The "Biltong" mouse perfectly mimics the Ataxia and Myopathy parts. It doesn't mimic the ALS part (at least not in the first 6 months of the mouse's life). This suggests that different mutations in the same gene might break the "railroad tracks" in slightly different ways, affecting different parts of the body.

The Bottom Line

This paper describes a new, valuable tool for scientists. By studying the "Biltong" mouse, researchers hope to:

1. Understand exactly how a tiny genetic typo causes muscle and balance problems.
2. Develop treatments that fix the "bent block" in the railroad tracks.
3. Test gene therapies that could silence the bad instructions, potentially helping humans with similar mutations.

In short, a mouse with a wobbly walk has given us a clearer map to navigate some of the most complex and devastating human neurological diseases.

Technical Summary

1. Problem Statement

Hereditary ataxias and myopathies are heterogeneous neurodegenerative disorders often caused by mutations in tubulin genes. Specifically, dominant mutations in the human gene TUBA4A are associated with a spectrum of conditions including Spastic Ataxia type 11 (SPAX11), Congenital Myopathy type 26 (CMYO26), and Frontotemporal Dementia/Amyotrophic Lateral Sclerosis type 9 (FTDALS9). While these conditions share a genetic etiology, they present with distinct clinical phenotypes affecting different cell types (cerebellar neurons, skeletal muscle, motor neurons). A significant gap exists in understanding the cell-type-specific mechanisms by which TUBA4A mutations drive these diverse pathologies. There is a critical need for animal models that can dissect these specific effects and serve as platforms for testing therapeutic strategies like allele-specific knockdown.

2. Methodology

The study employed a forward genetics approach combined with modern genomic and molecular techniques:

• ENU Mutagenesis Screen: Researchers screened N-ethyl-N-nitrosourea (ENU) mutagenized C57BL/6J mice to identify new models of neurological disease. A male mouse exhibiting muscle wasting and intention tremor at ~4 weeks of age was identified (nicknamed "Biltong").
• Breeding Strategy: Due to breeding difficulties, the line was propagated via in vitro fertilization (IVF) using BALB/cByJ oocytes. The line was maintained on a mixed C57BL/6J (B6) and BALB/cByJ (BALB) background.
• Genetic Mapping: A genome-wide SNP panel (141 markers) was used on N2 offspring (22 affected, 22 unaffected) to map the mutation. Fine mapping narrowed the locus to a ~25 Mbp region on Chromosome 1.
• Sequencing: Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) identified two candidate coding variants within the mapped interval:
  1. Stk36 (Y1003N)
  2. Tuba4a (Q176P)
• CRISPR Validation: Both variants were independently CRISPR-engineered into wild-type C57BL/6J mice to determine causality.
• Phenotyping: Extensive longitudinal phenotyping was conducted at 22 days, 30 days, 9 weeks, and 6 months, including:
  • Behavioral: Inverted wire hang tests, gait observation.
  • Neuromuscular: Electromyography (EMG) for nerve conduction velocity (NCV), compound muscle action potential (CMAP), and repetitive nerve stimulation (RNS).
  • Histopathology: Masson's trichrome staining, immunohistochemistry (Calbindin for Purkinje neurons, ChAT for motor neurons), and immunofluorescence for Neuromuscular Junctions (NMJs).
  • Ultrastructure: Transmission Electron Microscopy (TEM) of skeletal muscle.
  • Molecular: Western blotting for TUBA4A protein levels.

3. Key Contributions

• Identification of a Novel Mouse Model: The study characterizes the "Biltong" mouse strain, which carries a dominant Tuba4a missense mutation (Q176P).
• Causality Confirmation: Through CRISPR engineering, the authors definitively proved that the Tuba4a^Q176P mutation, and not the co-occurring Stk36^Y1003N variant, is responsible for the observed phenotypes.
• Cell-Type Specificity: The model demonstrates that the Tuba4a^Q176P mutation causes severe cerebellar Purkinje neuron degeneration and skeletal muscle myopathy but spares spinal motor neurons. This distinguishes it from the FTDALS9 phenotype often associated with TUBA4A mutations in humans.
• Mechanistic Insight: The study reveals that the mutation leads to a dominant-negative or toxic gain-of-function effect, evidenced by reduced total TUBA4A protein levels in affected tissues and embryonic lethality in homozygotes.

4. Key Results

• Genetics: The mutation is a missense substitution (n.A626C, p.Gln176Pro) in Tuba4a. The Q176 residue is highly conserved across species and located near other known pathogenic variants (P173R/S and T179I).
• Inheritance: The trait is autosomal dominant with full penetrance. Homozygous mutants are not viable postnatally, suggesting embryonic lethality.
• Phenotype Progression:
  • Onset: Mice appear normal at 3 weeks. By 30 days, they exhibit ataxia, intention tremor, and muscle atrophy.
  • Cerebellum: Calbindin staining shows rapid degeneration of Purkinje neurons (PNs) starting between 22 and 30 days. By 6 months, nearly all PNs are lost, except for those in lobule X, which are spared.
  • Skeletal Muscle: Histology reveals myofibrillar disorganization, central nuclei, vacuoles, ringbinden-like fibers, and fibrosis. TEM confirms Z-band streaming, multilamellar bodies, and mitochondrial mislocalization.
  • Neuromuscular Junction (NMJ): There is progressive denervation of the soleus and plantaris muscles, with decreased innervation observed as early as 30 days. However, nerve conduction velocity and CMAP amplitudes remain normal, indicating the defect is at the NMJ or muscle level, not the axon.
  • Motor Neurons: Crucially, unlike ALS models, there is no loss of spinal motor neurons or reduction in peripheral motor axon counts at 6 months.
• Protein Levels: Western blots show a significant decrease in TUBA4A protein levels in the cerebellum and soleus muscle of mutant mice compared to wild-type, despite the presence of the mutant allele.
• Validation: Tuba4a^Q176P knock-in mice recapitulated all Biltong phenotypes (ataxia, muscle pathology, PN loss) by 9 weeks. Stk36^Y1003N knock-in mice showed no phenotype.

5. Significance

• Disease Modeling: The Biltong mouse is a highly specific model for SPAX11 and CMYO26, capturing the cerebellar and muscular aspects of TUBA4A pathology without the confounding motor neuron degeneration seen in FTDALS9. This allows researchers to isolate the mechanisms of tubulin dysfunction in Purkinje cells and skeletal muscle.
• Therapeutic Development: The model provides a robust platform for testing gene therapies, such as allele-specific silencing (ASOs or CRISPR) to target the mutant Tuba4a allele while preserving the wild-type copy, which is crucial given the dominant nature of the mutation.
• Pathophysiological Insight: The findings suggest that TUBA4A mutations can have distinct, cell-type-specific consequences. The sparing of motor neurons in this model implies that the mechanisms driving SPAX11/CMYO26 may differ from those driving FTDALS9, or that the specific Q176P mutation lacks the toxicity required to kill motor neurons within the mouse lifespan.
• Fertility Link: The study notes breeding difficulties and sperm agglutination in mutants, potentially linking the model to human TUBA4A-associated infertility and zygotic arrest, though this requires further investigation.

In summary, this paper successfully identifies and validates a novel mouse model that decouples the cerebellar and muscular effects of TUBA4A mutations from motor neuron degeneration, offering a precise tool for studying tubulinopathies and developing targeted therapies.